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In the past few decades, as a result of their anti-inflammatory properties, n-3 long chain 
polyunsaturated fatty acids (n-3 LC-PUFAs), have gained greater importance in the 
regulation of inflammation, especially in the central nervous system (in this case known 
as neuroinflammation). If sustained, neuroinflammation is a common denominator of 
neurological disorders, including Alzheimer’s disease and major depression, and of aging. 
Hence, limiting neuroinflammation is a real strategy for neuroinflammatory disease therapy 
and treatment. Recent data show that n-3 LC-PUFAs exert anti-inflammatory properties 
in part through the synthesis of specialized pro-resolving mediators (SPMs) such as 
resolvins, maresins and protectins. These SPMs are crucially involved in the resolution 
of inflammation. They could be good candidates to resolve brain inflammation and to 
contribute to neuroprotective functions and could lead to novel therapeutics for brain 
inflammatory diseases. This review presents an overview 1) of brain n-3 LC-PUFAs as 
precursors of SPMs with an emphasis on the effect of n-3 PUFAs on neuroinflammation, 
2) of the formation and action of SPMs in the brain and their biological roles, and the 
possible regulation of their synthesis by environmental factors such as inflammation and 
nutrition and, in particular, PUFA consumption.
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INTRODUCTION
Inflammation is a critical process in host defense, facilitating tissue repair, regeneration and 
maintenance of homeostasis. However, if uncontrolled, it becomes a chronic low-grade inflammation 
that is characterized by the production of pro-inflammatory cytokines and adipokines leading to 
tissue damage and loss of function (López-Vicario et al., 2016). This chronic low-grade inflammation 
is observed in many chronic pathologies including neurodegenerative diseases and also in aging. 
Hence it becomes a significant public health concern and constitutes a financial burden that impacts 
millions worldwide (Serhan, 2017b). It is thus of importance to find treatments that ensure resolution 
of inflammation in a specific time-limited manner. Nutrition has gained importance in recent 
years since nutriments such as n-3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory 
properties (Calder, 2016; Calder et al., 2017). They exert their effect in part through their conversion 
into bioactive lipid mediators called specialized pro-resolving mediators (SPMs) that underlie most 
of the beneficial effects attributed to their precursors (Serhan, 2014; López-Vicario et al., 2016). 
Recently, attention has been paid to these derivatives in the regulation of neuroinflammation. In this 
review, we present an overview of brain n-3 PUFAs and their effect on neuroinflammation and of the 
formation and mechanisms of the action of SPMs in the brain.
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BRAIN N-3 PUFAS AS PRECURSORS 
OF SPMs
Brain n-3 PUFAs
The brain contains high levels of PUFAs (25–30%) that are 
mainly docosahexaenoic acid (DHA, n-3 PUFA) (12–14% of 
total fatty acids) and arachidonic acid (AA, n-6 PUFA) (8–10% of 
total fatty acids) (Carrie et al., 2000; Xiao et al., 2005; McNamara 
and Carlson, 2006; Little et al., 2007; Chung et al., 2008; Joffre 
et al., 2016). There are regional differences: the hippocampus and 
prefrontal cortex contain the highest DHA content whereas the 
hypothalamus has the lowest (Carrie et al., 2000; Xiao et al., 2005; 
Joffre et al., 2016). There are also cellular differences: astrocytes, 
oligodendrocytes, and microglial cells (representing respectively 
70%, 10–15% and 10–15% of brain glial cells; Renaud et al., 
2015) contain DHA in different proportions. DHA represents 
10–12% in astrocytes, 5% in the oligodendrocytes and up to 2% 
in microglial cells (Bourre et al., 1984; Rey et al., 2018). Neurons 
cannot synthesize long-chain PUFAs (LC-PUFAs) but can 
incorporate them in their membranes: DHA represents 8.3% of 
the total fatty acids in neurons (Bourre et al., 1984).
Numerous studies have discussed the transport of DHA 
through the blood–brain barrier (BBB). DHA enters the brain as 
unesterified DHA that is the major pool supplying the brain with 
DHA. However, the precise mechanisms of entry are still not 
fully described. Some transporters facilitate the uptake of DHA 
into the brain: fatty acid transport proteins (FATPs), fatty acid 
translocase (CD36) and major facilitator superfamily domain 
containing 2A (MFSD2A) (Chouinard-Watkins and Bazinet, 
2018). Fernandez et al. (2018) recently reported that a member 
of the long-chain acyl-CoA synthetase (ACSL) family, ACSL6, 
is also involved in brain DHA uptake but its role has yet to be 
determined (Fernandez et al., 2018).
This brain fatty acid composition can be affected by 
environmental factors such as nutrition, something to which 
individuals are continuously exposed. Indeed, the PUFA content 
in all brain structures is strongly impacted by the PUFAs present 
in the diet (Alashmali et al., 2016; Joffre et al., 2016). A diet rich in 
n-3 PUFAs (DHA found in fish or its precursor, alpha-linolenic 
acid, found in vegetable oil) increases brain DHA in rodents 
(Hiratsuka et al., 2009; de Theije et al., 2015; Skorve et al., 2015; 
Kitson et al., 2016). However, DHA supplementation is more 
effective than alpha-linolenic supplementation in increasing 
the DHA content in the brain (Lacombe et al., 2017; Rey et al., 
2019). In rodents, DHA supplementation from 16 weeks to 16 
months or from 20 to 22 months of age compensates a DHA 
decrease due to aging (Little et al., 2007; Labrousse et al., 2012; 
Bascoul- Colombo et al., 2016). On the other hand, a diet deficient 
in n-3 PUFAs decreases brain DHA in all brain structures, with 
the hippocampus, containing most DHA, being the most affected 
and the hypothalamus the least affected (Delpech et al., 2015b; 
Joffre et al., 2016; Manduca et al., 2017).
Studies from Broadhurst and Crawford suggest that the amount 
of DHA incorporated into the brain depends on the complexity 
of the brain structure and on behavior development (Crawford 
et al., 1999; Broadhurst et al., 2002). A decrease in brain DHA 
induced by a deficient diet during gestation and lactation can 
be reversed by 2-month DHA supplementation at weaning (Orr 
et al., 2013). The organism also adapts its metabolism to an n-3 
PUFA deficiency condition: the half-life of DHA increases in the 
brain to reduce its loss (Rapoport et al., 2007) and the activity of 
the enzymes responsible for DHA conversion, the ∆6 desaturase 
and elongase, is increased in the liver (Cho et al., 1999; Wang 
et al., 2005; Igarashi et al., 2007). Brain cells are also impacted 
by dietary PUFA supply. An n-3 PUFA deficient diet decreases 
DHA in astrocytes, neurons and oligodendrocytes (Bourre et al., 
1984) whereas n-3 PUFA supplementation increases DHA levels 
in glial cells (Bowen and Clandinin, 2005; Destaillats et al., 2010). 
Moreover, we recently showed that the fatty acid composition of 
the microglial cells is also modulated by n-3 PUFA dietary intake 
during the gestation/lactation period. Maternal n-3 LC-PUFA 
dietary supplementation during gestation and lactation increases 
the DHA level in the offspring’s microglia at P21 as compared 
with a maternal diet that contains equilibrated levels of n-6 and 
n-3 PUFA precursors (Rey et al., 2018). Interestingly, maternal 
n-3 PUFA deficiency does not impact the DHA level suggesting 
that microglial cells are protected from n-3 PUFA deficiency 
(Rey et al., 2018).
n-3 PUFAs as Regulators of 
Neuroinflammation
n-3 PUFAs have powerful anti-inflammatory properties (Calder, 
2005). They play an important role in the regulation of the 
synthesis and release of pro-inflammatory mediators (Delpech 
et al., 2015b; Hanisch and Kettenmann, 2007; Cunningham 
and Sanderson, 2008; Yirmiya and Goshen, 2011; Pascual et al., 
2012). Pro-inflammatory factors include interleukin-1 beta 
(IL-1β), interleukin-6 (IL-6) and tumor necrosis factor alpha 
(TNF-α) and play a role in neuronal plasticity (Delpech et al., 
2015b; Yirmiya and Goshen, 2011). If sustained, uncontrolled 
inflammation can lead to neuronal damage that is involved in 
many neuronal pathologies (Blais and Rivest, 2003; Layé, 2010; 
Solito and Sastre, 2012). Hence, limiting the inflammation and 
enhancing the resolution of inflammation is of great interest.
Evidence in Humans
In humans, the anti-inflammatory properties of n-3 PUFAs 
were first identified in epidemiological studies in Eskimos that 
consume a lot of n-3 LC-PUFAs from eating fish (Dyerberg and 
Bang, 1979; Kromann and Green, 1980; Simopoulos, 2008). 
Clinical studies have highlighted the beneficial effect of n-3 
LC-PUFAs in chronic inflammatory and autoimmune diseases. 
Indeed, fish oil supplementation decreases pro-inflammatory 
cytokine expression, such as IL-1β in blood monocytes, and 
improves the symptoms of patients suffering from rheumatoid 
arthritis (Kremer et al., 1990; James et al., 1997; Kremer, 2000) 
or multiple sclerosis (Stewart and Bowling, 2005; Weinstock-
Guttman et al., 2005). Moreover, DHA supply significantly 
decreases the circulating inflammatory markers and the 
oxidative stress (Freund-Levi et al., 2006; Kiecolt-Glaser et al., 
2012). DHA supply for several months also improves the working 
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and long-term memories in patients with moderate cognitive 
alterations (Freund-Levi et al., 2006; Lee et al., 2013).
Evidence in Animals
In animals, numerous studies have demonstrated the anti-
inflammatory properties of n-3 PUFAs in the brain. In 
lipopolysaccharide (LPS)-, or IL-1β-, induced inflammation 
models, dietary n-3 LC-PUFA supplementation in adulthood 
prevents LPS-induced hippocampal increase of pro-inflammatory 
cytokines IL-1β and TNF-α in rats and mice (Orr et al., 2013; 
Dehkordi et al., 2015; Rey et al., 2019). A dietary supply in 
eicosapentaenoic acid (EPA) decreases the production of LPS-
induced pro-inflammatory cytokines IL-1β, IL-6 and TNF-α 
in the hippocampus and increases the production of anti-
inflammatory cytokines IL-10 and IL-4 in both rats (Kavanagh 
et al., 2004; Lonergan et al., 2004; Dong et al., 2017) and mice 
(Shi et al., 2016). This modification is associated with a decrease 
in the phosphorylation of c-Jun and c-Jun N-terminal kinase 
proteins and in nuclear factor-kappa B (NFκB) that regulate 
inflammation (Lonergan et al., 2004; Shi et al., 2016). EPA dietary 
supply attenuates the activation of microglial cells and astrocytes 
triggered by an intracerebral IL-1β administration and increases 
the production of IL-10 in the hippocampus in rats (Song and 
Horrobin, 2004; Song et al., 2008; Dong et al., 2017). Following 
dietary DHA supplementation, there is an increase of DHA in 
the phospholipid and free fatty acid fractions. However, only the 
unesterified DHA is necessary to attenuate neuroinflammation. 
Nevertheless, the DHA phospholipid pool is an important source 
of unesterified DHA (Orr et al., 2013). On the contrary, in mice, 
an n-3 PUFA deficiency from the first day of gestation to weaning 
increases the expression of pro-inflammatory markers in the 
hippocampus and an alteration in the motility and the phenotype 
of microglial cells and alters synaptic plasticity (Lafourcade 
et al., 2011; Madore et al., 2014; Thomazeau et al., 2017). Using 
the model of intraperitoneal (ip) injection of LPS, we showed 
that IL-6 expression is strongly induced in n-3 PUFA-deficient 
mice whereas sickness behavior is down-regulated via the 
impairment of IL-6 signaling in the brain (Mingam et al., 2008). 
Moreover, when the deficiency continues in adulthood, it alters 
GABAergic, dopaminergic and cholinergic neurotransmission 
(Zimmer et  al., 2000; Aid et al., 2003; Chalon, 2006; Larrieu 
et  al., 2014) and anxiety-related, depressive-like behaviors that 
can be compared with autistic behavior in adults (Mingam et al., 
2008; Larrieu et al., 2012; Larrieu et al., 2014; Hughes et al., 2016; 
Manduca et al., 2017). Following ip injection of LPS, n-3 PUFA-
deficient mice display altered hippocampal synaptic plasticity 
that likely contributes to spatial memory impairment and higher 
glucocorticoid levels (Delpech et al., 2015b). On the contrary, 
an n-3 PUFA dietary supply improves emotional behavior 
alteration and memory deficit in rats (Song and Horrobin, 2004; 
Song et al., 2008; Dong et al., 2017), restores social and memory 
performance altered in autism models and improves depressive 
symptoms in both mice (Pietropaolo et al., 2014; Madore et al., 
2016; Weiser et al., 2016) and rats (Bove et al., 2018; Morgese 
et al., 2018). Of note, n-3 LC-PUFA dietary supplementation 
attenuates depressive symptoms in depressed patients presenting 
inflammation (McNamara, 2015; Rapaport et al., 2016; Larrieu 
and Layé, 2018; Layé et al., 2018). This protective effect seems 
to be linked to EPA which could target microglia to reduce 
neuroinflammation (Bazinet et al., 2019). n-3 LC-PUFAs could 
also modulate neuroinflammation through their effect on the 
HPA axis (Larrieu et al., 2014; Hughes et al., 2016; Larrieu 
and Layé, 2018). With Alzheimer’s disease, β-amyloid triggers 
depressive symptoms through neuroinflammatory processes 
that could be improved by dietary n-3 PUFAs (Bove et al., 
2018; Morgese et al., 2018). Altogether these data reinforce the 
importance of n-3 PUFAs as regulators of inflammation and 
associated depressive symptoms.
Another way to modulate neuroinflammation is to administer 
n-3 PUFAs directly into the brain or peripherally. Indeed, a 
24-hour intracerebroventriculary (icv) DHA brain infusion 
attenuates hippocampal neuroinflammation initiated by icv 
LPS in mice (Orr et al., 2013). In a mouse model of cerebral 
ischemia, DHA icv administration inhibits NFκB activation 
and cyclooxygenase-2 (COX-2) expression in the hippocampus 
(Marcheselli et al., 2003). Moreover, intrathecal injection of 
DHA decreases microglial activation, mitogen-activated protein 
kinase (MAPK) phosphorylation and the production of pro-
inflammatory cytokines in the spinal cord of mice (Lu et al., 
2013). In addition, in a model of traumatic brain injury in rats, n-3 
PUFA ip injection attenuates microglial-induced inflammation 
by inhibiting the NFκB pathway (Chen et al., 2017).
Dietary n-3 LC-PUFA supplementation requires the use of 
fish oil. However, fish oil may provide confusing factors such as 
vitamins, for example. Thus, the use of Fat-1 transgenic mice that 
convert n-6 to n-3 PUFAs through a desaturase from C. elegans 
is a model that enables the elimination of confusing factors 
provided by the diet (Kang et al., 2004). Such mice have higher 
DHA levels in the hippocampus and cortex (Delpech et al., 2015a; 
Boudrault et al., 2010; Orr et al., 2013). They express less COX-2 
(involved in the production of lipid mediators) in the cortex 
than wild type mice (Boudrault et al., 2010). They are protected 
against cognitive deficits induced by ip LPS injection through a 
decrease in neuroinflammation (Orr et al., 2013; Delpech et al., 
2015a). This is associated with a decrease in microglial activation 
(Orr et al., 2013).
Evidence in In Vitro Studies
In vitro studies have shown that n-3 PUFAs have an inhibitory 
effect on the production of pro-inflammatory cytokines in 
microglial cells. Indeed, in the microglial cell line or primary 
culture microglial cells, DHA prevents LPS-induced NKκB 
activation and then cytokine production by inhibiting LPS 
receptor presentation and decreases the oxidative stress, nitric 
oxide (NO) production and inducible nitric oxide synthase 
(iNOS) expression (De Smedt-Peyrusse et al., 2008; Lu et al., 2010; 
Antonietta Ajmone-Cat et al., 2012; Pettit et al., 2013; Chen et al., 
2014; Corsi et al., 2015; Fourrier et al., 2017; Inoue et al., 2017;). 
Moreover, DHA prevents LPS-induced MAPK phosphorylation 
(MAPK pathway playing essential roles in the expression of 
inflammatory molecules) and induces peroxisome proliferator-
activated receptor (PPAR)-γ nuclear translocation that exerts 
anti-inflammatory effects (Antonietta Ajmone-Cat et al., 2012). 
Of interest, EPA also affects the production of TNF-α, IL-6 and 
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NO by inhibiting NFκB phosphorylation via sirtuin-1 (SIRT-1) 
(Moon et al., 2007; Chen et al., 2014; Inoue et al., 2017). It is likely 
that DHA attenuates the inflammatory response in LPS-activated 
microglia by remodeling lipid bodies that are dynamic organelles 
in which DHA is incorporated and by altering their interplay 
with mitochondria and other associated organelles (Tremblay 
et al., 2016). In addition, DHA and EPA are able to enhance 
myelin or amyloid β (Aβ) peptide phagocytosis that is associated 
with a shift in microglial polarization toward the beneficial M2 
phenotype and to a decrease in pro-inflammatory cytokine 
production (Hjorth et al., 2013; Chen et al., 2014).
This modulation of neuroinflammation induced by n-3 
LC-PUFA supply is attributed, in part, to SPM synthesis (Barden 
et al., 2016). In the various phases of inflammatory response, 
prostaglandins, leukotrienes and thromboxane are synthesized 
first (Figure 1). They permit the propagation of inflammation. 
They also stimulate the synthesis of SPMs with pro-resolutive 
properties (Levy et al., 2001; Serhan and Savill, 2005).
n-3 PUFA-Derived SPMs and Their 
Synthesis Pathway
Many of the n-3 PUFA-derived immunomodulators that orchestrate 
the inflammatory response are lipids (Doyle et al., 2018). 
Some of them are involved in the regulation of inflammation 
(prostaglandins, thromboxanes, leukotrienes, etc.) and others 
are implicated in the resolution of inflammation (resolvins, 
protectins and maresins). There is a temporal shift in the lipid 
mediator synthesis from the initiation of inflammation to the 
resolution that allows the formation of different lipid mediators at 
different times (Figure 1). Here we have focused on SPMs, which 
are of great interest since they permit a return to homeostasis 
(Serhan et al., 2015; Sugimoto et al., 2016). Charles N. Serhan first 
identified these SPMs at the periphery and characterized their 
anti-inflammatory and pro-resolutive properties (Serhan et al., 
2000). SPMs actively orchestrate and finely tune the inflammatory 
response. They decrease pro-inflammatory cytokines and increase 
anti-inflammatory cytokines, accelerate the phagocytosis of 
cellular debris and dead cells without immune suppression. A 
failure in the resolution of inflammation is detrimental for tissue 
and contributes to a chronic inflammatory response.
BIOSYNTHESIS AND BIOLOGICAL ROLES 
OF n-3 PUFA-DERIVED SPMs
Biosynthesis of n-3 PUFA-Derived SPMs
Free (unesterified) n-3 LC-PUFAs are released from membrane 
phospholipids through the action of phospholipases A2 
(PLA2) in response to stimulation. DHA is hydrolyzed by 
calcium independent PLA2 (iPLA2) from phospholipids and 
plasmenylethanolamine-PLA2 from plasmalogens (Farooqui 
and Horrocks, 2006). After this step, n-3 LC-PUFAs undergo an 
enzymatic conversion to generate SPMs (Figures 2 and 3).
FIGURE 1 | Molecular events implicated in inflammation and the resolution of inflammation. AA, arachidonic acid; DHA, docosahexaenoic acid;  
EPA, eicosapentaenoic acid; IL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor. 
FIGURE 2 | Main synthesis pathway of n-3 long-chain PUFA-derived lipid 
mediators. ALX/FpR2, lipoxin A4 receptor/formyl peptide receptor 2; BLT1, 
Leukotriene B4 receptor 1; ChemR23, chemokine-like receptor 1; COX-2, 
cyclooxygenase-2; CYP450, monoxygenases cytochrome P450; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; GPR, G protein-
coupled receptor; HDHA, hydroxy-docosahexaenoic acid; HEPE, hydroxy-
eicosapentaenoic acid; HpDHA, hydroperoxyl-docosahexaenoic acid; 
HpEPE, hydroperoxy-eicosapentaenoic acid; LOX, lipoxygenases; PLA2, 
phospholipase A2.
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n-3 PUFA-derived SPMs are synthesized mainly from 
DHA and EPA via COX-2, lipoxygenases (LOX) and CYP450 
monoxygenases (CYP450). In the brain, 15-LOX, 12/15-
LOX and 5-LOX are the most abundant LOX and are widely 
distributed, suggesting the potential production of SPMs 
(Shalini et al., 2017). They are expressed in the second step 
of inflammation in the hippocampus (Czapski et al., 2010; 
Birnie et al., 2013). 15-LOX is involved in neurodegeneration 
and neurotoxicity due to the increased oxidative stress it 
generates in models of Alzheimer’s disease (Pratico et al., 
2004; Wang et al., 2015) and brain ischemia (Yigitkanli et al., 
2017). However, it is also implicated in neuroprotection (Sun 
et al., 2015). Indeed, it increases the production of 12-HETE 
and 15-HETE that promote the activation of PPARγ that is 
neuroprotective through its anti-inflammatory properties. 
The inhibition of 15-LOX induces hippocampus-dependent 
cognitive alterations (Shalini et al., 2017). Indeed, it prevented 
long term potentiation, a major molecular mechanism 
that describes the strengthening of synapses and underlies 
learning and memory. Moreover, 15-LOX deletion drastically 
decreases SPM production in the brain while SPMs also 
modulate synaptic plasticity (Park et al., 2011; Shalini et al., 
2017). In the brain, the inducible COX-2 is activated via an 
NFκB pathway (Nadjar et al., 2005). COX-2 catalyzes the first 
step of the synthesis of prostaglandins and thromboxanes 
derived from n-6 PUFAs that contribute to the initiation 
of inflammation (Davidson et al., 2001; Salinas et al., 2007; 
Engstrom et al., 2012). COX-2 also produces hydroxyl fatty 
acids from DHA in both an aspirin-dependent and aspirin-
independent manner (Serhan et al., 2002; Oh et  al., 2011; 
Gabbs et al., 2015; Nebert, 2017). In response to LPS, COX-2 
is rapidly expressed in the hippocampus (Czapski et al., 2010; 
Rey et al., 2019). Inhibition of COX-2 delays resolution of 
acute inflammation (Schwab et al., 2007). CYP450s play 
a complex role in inflammation by producing n-6 PUFA-
derived bioactive mediators such as epoxides that are anti-
inflammatory in monocytes and macrophages (Bystrom et al., 
2011; Fleming, 2011; Nebert et al., 2013; Gilroy et al., 2016).
DHA is the precursor of resolvins D1-6 (RvD1-6), neuroprotectin 
D1 (NPD1) and maresins 1–2 (Mar1-2) which all have pro-resolutive 
and anti-inflammatory properties (Spite and Serhan, 2010; Halade 
et al., 2018). RvD1-6 are synthesized from DHA but RvD1 is the 
most studied because it has powerful anti-inflammatory and pro-
resolutive properties. DHA is converted into monohydroxy DHA, 
17-hydroxy docosahexaenoic acid (17-HDHA) by acetylated COX-
2, CYP450 and 15-LOX (Barden et al., 2016; Halade et al., 2018) 
and then into RvD1 by 5-LOX (Sun et al., 2007; Recchiuti, 2013). 
DHA is also converted into di-hydroxy-DHA, termed protectin D1 
(PD1) or neuroprotectin D1 (NPD1) when produced in the central 
nervous system by 5- and 15-LOX (Hong et al., 2003; Aursnes et al., 
2014; Kuda, 2017; Doyle et al., 2018). Acetylated COX-2 permits the 
synthesis of aspirin-triggered PD1 (AT-PD1) which has powerful 
protective effects (Bazan et al., 2012). DHA is transformed into Mar 
1-2 by 12/15-LOX via the synthesis of 14-HDHA (Serhan et al., 
2009; Barden et al., 2016; Halade et al., 2018).
EPA is the precursor of resolvins E1 (RvE1), E2 and E3 
that have many biological roles (Serhan et al., 2000; Rey et al., 
2016; Halade et al., 2018). It is converted by aspirin-triggered 
acetylated COX-2 or CYP450 into 18R-hydroxyeicosapentaenoic 
acid (18R-HEPE), that is transformed into RvE1 or E2 by 5-LOX 
(Ohira et al., 2010; Barden et al., 2016) or into RvE3 by 15-LOX 
(Isobe et al., 2012).
FIGURE 3 | Biochemical structures of the main n-3 long-chain PUFA-derived lipid mediators. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HpDHA, 
hydroperoxyl-docosahexaenoic acid; HpEPE, hydroperoxy-eicosapentaenoic acid; Mar1, maresin 1; NPD1, neuroproetectin D1; RvD1, resolvin D1; RvE1, 
resolvin E1. (Serhan and Petasis, 2011; Serhan et al., 2015)
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Little is known concerning the pharmacokinetics and dynamics 
of oxylipins. They are synthesized in situ, reinforcing the importance 
of the fatty acid composition of the brain. They are not stored, 
but produced on demand and they are unstable, being 
rapidly metabolized.
The structure of all derivatives is highly preserved in the 
evolution from fish to humans suggesting their great bioactive 
role in all organ systems. Dysfunction of SPM production can be 
due to insufficient EPA and DHA supply leading to inadequate 
production of SPMs or to the polymorphism of the enzymes 
involved in their synthesis or to a defect in the binding of SPMs 
to their receptors (Sugimoto et al., 2016). In humans, reduced 
SPM production is associated with chronicity and the magnitude 
of persistent inflammation. SPMs have multiple biological roles 
in the maintenance of homeostasis.
Biological Roles of DHA-Derived SPMs
In human serum, the DHA-derivatives represent 30.7% of the 
identified SPMs (Colas et al., 2014; Serhan et al., 2018). RvD1, 
PD1 and Mar1 were detected at 30.9 pg/mL, 5.6 pg/mL and 21.2 
pg/mL, respectively. They act in the nanomolar or picomolar 
range as compared with DHA and EPA acting in the micromolar 
range (López-Vicario et al., 2016; Clària et al., 2017; Serhan, 
2017a; Wang and Colgan, 2017; Rosenthal et al., 2018).
Resolvins
RvDs have been identified in mice peritoneal exudates (Serhan 
et  al., 2002). They have many properties at the periphery: 
protection against bacterial infection, prevention of leucocyte 
infiltration, inhibition of the production of cytokines, etc. (Spite 
et al., 2009; Serhan and Petasis, 2011; Chiang et al., 2012; Dalli 
et al., 2013a; Winkler et al., 2016). RvD1 and its precursor 
metabolites have been detected in the brain.
In vitro, 17-HDHA has been found in glial cells after DHA 
and inflammatory stimulus (Hong et al., 2003). In vivo, RvD1 
has been identified in mouse brain following cerebral ischemia 
(Marcheselli et al., 2003). Intravenous (iv) DHA injection 
increases RvD1 levels in rats suggesting the conversion of DHA 
into RvD1 (Mulik et al., 2016). RvD1 acts through the lipoxin 
A4 receptor/formyl peptide receptor 2 (ALX/Fpr2) in rodents 
and the G protein coupling receptor 32 (GPR32) in humans 
(Recchiuti, 2013) in the picomolar range but induces biological 
effects in the nanomolar range (Sun et al., 2007; Krishnamoorthy 
et al., 2010). An overexpression of ALX/Fpr2 or GPR32 increases 
in phagocytosis by macrophages whereas their deletion decreases 
the phagocytosis response (Perretti et al., 2002; Krishnamoorthy 
et al., 2010; Cooray et al., 2013). RvD1 regulates the expression 
of specific micro-RNA (miR) to control the intensity and the 
length of inflammation via the regulation of target genes such 
as inflammatory cytokine genes (Fredman and Serhan, 2011; 
Recchiuti et al., 2011; Rey et al., 2016; Bisicchia et al., 2018). 
RvD1 increases the expression of miR-21, miR-146b and miR-
219 and decreases the expression of miR-208a in macrophages 
and peritoneal exudates in mice (Recchiuti et al., 2011; 
Krishnamoorthy et al., 2012). RvD1 modulates miR-155, miR-
146, miR-21 and miR-219 in microglial cells (Rey et al., 2016). 
These miRs have different biological roles: miR-21 is essential to 
the production of anti-inflammatory cytokine IL-10, miR-146 
regulates the transcription of cytokines, chemokines and their 
receptor, miR-219 decreases the transcription of TNF-α and miR-
208a regulates the activation of NFkB (Recchiuti et al., 2011).
RvD1 controls the inflammatory response in many animal 
models via its anti-inflammatory and pro-resolutive properties. 
In rats, endogenous RvD1 levels decrease at the beginning of 
inflammation and then increase during the resolution phase 
(Sun et al., 2014). Recent studies describe the anti-inflammatory 
properties of RvD1 in microglia and astrocyte cell cultures 
(Abdelmoaty et al., 2013; Li et al., 2014; Rey et al., 2016). Indeed, 
in BV2 microglia cell culture, RvD1 promotes the IL-4-induced 
M2 phenotype (Li et al., 2014) and inhibits LPS-induced pro-
inflammatory cytokines (Rey et al., 2016). In astrocyte cell 
culture, RvD1 attenuates LPS-induced TNF-α (Abdelmoaty et al., 
2013). In vivo, in a model of remote damage, Bisicchia et al. recently 
show in rats that RvD1 promotes functional recovery and reduces 
neuroinflammation via miRs (Bisicchia et al., 2018).
Biological Roles of RvD1 in Humans
The effect of RvD1 has been studied in patients suffering from 
Alzheimer’s disease. This pathology is characterized by an 
increase in microglial activation and in pro-inflammatory 
cytokine production in the brain (Griffin et al., 1989; Cagnin 
et al., 2001). Interestingly, RvD1 levels in the cerebrospinal fluid 
are positively correlated with the enhancement of cognitive 
functions of patients with dementia (Wang et al., 2015). Indeed, 
RvD1 may be involved in Aβ phagocytosis. This has been shown 
in vitro in macrophages isolated from Alzheimer’s patients 
(Mizwicki et al., 2013; Famenini et al., 2017). Thus the decrease 
in RvD1 levels in Alzheimer patients’ brains could contribute to 
the evolution of the disease.
Biological Roles of RvD1 in Rodents
RvD1 attenuates the pro-inflammatory status in the central 
nervous system. Indeed, an intrathecal injection of 17R-HDHA 
decreases TNF-α release in the spinal cord in rats (Abdelmoaty 
et al., 2013). Orr et al. show that icv injection of 17S-HDHA into 
mice decreases the expression of hippocampal pro-inflammatory 
cytokines IL-1β and TNF-α induced by LPS acute icv injection 
(Orr et al., 2013). However, these authors detected NPD1 but did 
not detect RvD1, suggesting that the effect of 17S-HDHA was 
rather due to the conversion of 17S-HDHA into NPD1. RvD1 
is also able to stimulate phagocytosis in macrophages (Rossi 
et al., 2015). Indeed, DHA and RvD1 induce the polarization of 
macrophages toward an M2 phagocytic phenotype in mice (Titos 
et al., 2011).
Studies have highlighted the protective role of RvD1 in 
the occurrence of cognitive deficits. Terrando et al. showed 
that an ip injection of 17-HDHA restores transmission and 
synaptic plasticity and prevents astrogliosis and cognitive 
decline in a systemic inflammation model in mice (Terrando 
et al., 2013). Conversely, an inhibition of 15-LOX, associated 
with a decrease in RvD1, alters synaptic plasticity and working 
memory as demonstrated in rats (Shalini et al., 2017). RvD1 
plays also a role during the recovery phase following cerebral 
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ischemia. Indeed, the precursor of 17-HDHA, 17-hydroperoxy 
docosahexaenoic acid (17-HpDHA), accumulates in the 
hippocampus of mice (Marcheselli et al., 2003). An ip chronic 
administration of 17R-HDHA synthesized by acetylated COX-
2, prevents cognitive deficits and attenuates motor disorders 
but doesn’t ameliorate microglial activation and sleep quality 
in mice (Harrison et al., 2015). Moreover, Fat-1 mice that have 
more brain n-3 LC-PUFAs, have higher hippocampus RvD1 
levels, associated with less cognitive deficits, a better neuronal 
survival, a decrease in astrocyte and microglial activation 
and a reduction in pro-inflammatory status following brain 
ischemia (Luo et al., 2014; Delpech et al., 2015a).
Studies have also highlighted the protective role of resolvins in 
the depressive-like behavior in rodents. Some of them have been 
recently reported by Furuyashiki et al. (Furuyashiki et al., 2019). 
An icv injection of RvD1, D2, E1, E2, or E3 significantly decreases 
LPS-induced depressive-like behavior in mice (Deyama et al., 
2017; Deyama et al., 2018a; Deyama et al., 2018b). Moreover, 
the occurrence of depressive-like behavior associated with pain 
can also be prevented by an intrathecal injection of 17R-HDHA 
that is associated with the decrease of pain perception and a 
restoration of dopamine and glutamate levels in the brain both 
in rats (Abdelmoaty et al., 2013) and mice (Klein et al., 2014). 
RvD1 and D2 have also positive effects in chronic mild stress-
induced depression and in post-myocardial infarct depression in 
rats (Gilbert et al., 2014) and mice (Ishikawa et al., 2017).
Biological Roles of RvD1 in In Vitro Models
The effects of RvD1 were tested on different brain cells. In 
microglial cells, RvD1 potentiates the effect of the anti-
inflammatory cytokine IL-4 in the activation of M2 phenotype 
of microglia (Li et al., 2014). Moreover, we showed that RvD1 
decreases LPS-induced pro-inflammatory cytokines (TNF-α, 
IL-6 and IL-1β) gene expression in microglial BV2 cells via the 
modulation of miRs (Rey et al., 2016). This suggests its pro-
resolutive activity in microglia. In astrocytes, RvD1 decreases 
TNF-α release induced by LPS injection (Abdelmoaty et al., 2013). 
In neurons from spinal nods, RvD1 increases neurite outgrowth 
(Shevalye et al., 2015). All these studies suggest that RvD1 can 
play a central role in the regulation of neuroinflammatory 
pathologies.
Other D resolvins have been identified in rodent brain: 
RvD2, RvD4 and RvD5 (Orr et al., 2013; Hashimoto et al., 2015; 
Winkler et al., 2016). RvD2 limits the activation of microglial 
cells and inhibits the TLR4/NFκB pathway (Tian et al., 2015). 
Moreover, chronic intrathecal RvD2 injection prevents the 
behavioral alterations induced by LPS central injection (Tian 
et al., 2015). It also prevents depressive-like behavior induced by 
ip LPS injection by regulating mammalian target of rapamycin 
complex 1 (mTORC1) complex (Deyama et al., 2017). RvD5 level 
is decreased in the brain of Alzheimer’s disease patients but its 
role has not yet been identified (Zhu et al., 2016).
Neuroprotectin
Di-hydroxy-DHA termed protection D1 (PD1) has been 
identified in blood, peritoneal neutrophils and neuroprotectin 
D1 (NPD1) in the brain in response to zymosan in mice (Hong 
et al., 2003). Marcheselli et al. have measured NPD1 production 
in mice hippocampus following brain ischemia (Marcheselli 
et al., 2003). One receptor for NPD1 has recently been identified 
as GPR37 (Qu and Caterina, 2018). NPD1 inhibits the oxidative 
stress in retinal epithelial cells and stimulates their proliferation 
(Bazan, 2009; Calandria and Bazan, 2010). NPD1 is also able 
to inhibit neovascularization via microglial cell ramification in 
mice (Sheets et al., 2013). In the central nervous system of mice, 
the NPD1 level greatly increases in the hippocampus following 
brain ischemia or acute central LPS injection (Marcheselli 
et al., 2003; Orr et al., 2013). Hence, NPD1 limits neutrophil 
infiltration, inhibits NFκB and then decreases pro-inflammatory 
gene expression (Marcheselli et al., 2003; Bazan et al., 2012; 
Yao et al., 2013). NPD1 levels decrease in the hippocampus of 
Alzheimer’s disease patients (Lukiw et al., 2005). It plays a role 
in cellular survival via anti-apoptotic protein induction and 
attenuates pro-inflammatory responses following Aβ exposure 
via NFκB regulation (Lukiw et al., 2005; Bazan, 2008; Asatryan 
and Bazan, 2017).
Maresins
Mar1 has been identified in mice peritoneal macrophages (Dalli 
et al., 2013b; Serhan et al., 2009). Its receptor has not been 
identified yet (Zhu et al., 2016). Mar1 is involved in the 
resolution of inflammation, prevents neutrophil infiltration, 
and increases the phagocytosis of apoptotic neutrophils by 
macrophages in a peritonitis murine model (Serhan et al., 2009). 
In a murine model of colitis, Mar1 decreases the expression of 
pro-inflammatory cytokines by inhibiting the NFκB pathway 
and activating the M2 phenotype in macrophages (Marcon 
et al., 2013). Mar1 and its precursor 14-HDHA have recently 
been identified in the hippocampus of mice (Orr et al., 2013). 
In post-mortem brain of Alzheimer’s disease patients, the 
Mar1 level is decreased (Zhu et al., 2016). In this pathology, its 
role is to stimulate Aβ plaque phagocytosis by microglial cells 
and to decrease inflammatory marker levels. Hence, Mar1 
may play an important role in the pathogenesis of Alzheimer’s 
disease (Zhu et al., 2016). In cerebral ischemia in mice, Mar1 
icv injection decreases inflammation and mitochondrial 
damage and also reduces neurological deficits via activation 
of SIRT-1 signaling (Xian et al., 2016; Xian et al., 2019). After 
spinal cord injury in mice, iv injection of Mar1 promotes 
resolution of inflammation (reducing pro-inflammatory 
cytokines, silencing pro-inflammatory signaling cascades 
and enhancing the M2 repair macrophage phenotype) and 
functional recovery (Francos-Quijorna et al., 2017). Mar1 also 
decreases in vitro neuronal death (Zhu et al., 2016).
Biological Roles of EPA-Derived SPMs
RvE1, and its precursor 18-HEPE, have been detected in the 
hippocampus of rats (Chen et al., 2011) and mice (Orr et al., 
2013; Siegert et al., 2017). In human serum, the EPA-derivatives 
represent 25.9% of the identified SPMs (Colas et al., 2014; Serhan 
et al., 2018).
RvE1 has been initially identified in mouse exudates (Serhan 
et al., 2000). RvE1 directly binds to its receptor ChemR23 or 
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CMKLR1 (chemokine-like receptor 1) (Ohira et al., 2010). It is 
also a partial agonist of LTB4 receptor (BLT1) (Arita et al., 2007). 
In the central nervous system, ChemR23 has been identified 
in the prefrontal cortex, hippocampus and brainstem (Guo 
et al., 2012), in microglial cells (Graham et al., 2009; Rey et al., 
2016) and in neurons (Xu et al., 2010). It is highly expressed in 
neurons, in microglial cells and in astrocytes in the post-mortem 
hippocampus of Alzheimer’s patient brain (Wang et al., 2015). 
This increase could be due to a compensatory mechanism to 
counter-balance the decrease in RvE1 in such patients (Wang 
et al., 2015). In vitro, RvE1 plays also a direct role in microglial 
cells by inhibiting microglial activation and pro-inflammatory 
cytokine release (Xu et al., 2013; Rey et al., 2016). RvE1 
and its precursor, 18R-HEPE, exert anti-inflammatory and 
anti-apoptotic properties (Hecker et al., 2018). Indeed, they 
restore mitochondrial dysfunction induced by inflammation 
in mononuclear blood cells. In vivo, RvE1 modulates the 
inflammatory profile and microglial activation in mice (Xu et al., 
2013; Harrison et al., 2015). Intraperitoneal injection of RvE1 
also modulates inflammation (by reducing Il-1β, Il-6 and IL-10 
levels in the prefrontal cortex) and decreases the measures of Aβ 
pathology in a murine model of Alzheimer’s disease (Kantarci 
et al., 2018). RvE1 and RvE2 centrally administered also reduce 
the LPS-induced depressive-like behavior through ChemR23 in 
mice (Deyama et al., 2018b). RvE1, a total agonist of ChemR23, 
is more effective than RvE2, which is only a partial agonist of this 
receptor (Serhan and Chiang, 2013).
REGULATION OF THE n-3 PUFA-DERIVED 
SPMs
Resolution of inflammation is an active process involving the 
regulation of the synthesis of numerous mediators in a tightly 
coordinated manner. The balance between n-3 PUFA-derived 
SPMs and the pro-inflammatory mediators determines the 
duration of the inflammatory response and the timing of 
resolution (Fredman et al., 2017).
Regulation of the n-3 PUFA-Derived SPMs 
by PUFA Consumption
We have previously shown that PUFA consumption leads to 
modifications in PUFA levels in the brain. The PUFA derivative 
levels and their biosynthetic enzyme expression also depend on 
dietary PUFAs.
SPM levels in peripheral organs and the brain are modulated 
by different dietary supplies of PUFAs (Figure 4). In humans 
supplemented with 2.4g/day of n-3 LC-PUFAs for 3 weeks 
(EPA+DHA), SPM levels are generally found to be between 20 
and 200 pg/mL (Mas et al., 2012). A shorter supplementation 
period (5 days) also increased DHA- and EPA- derived SPMs 
in plasma, especially 18-HEPE, RvE1, 17- and 14-HDHA 
(Barden et al., 2014). In another study, supplementing patients 
with a higher fish oil supplement (17.6g/day EPA+DHA) for 
24h, only PD1 is detected in the plasma and this increases from 
1.0–1.2 pg/mL to 2.7–4.1 pg/mL (Skarke et al., 2015; Barden 
et al., 2016). These differences in SPM levels in human plasma 
could be due to differences in study design, dose, duration 
of n-3 fatty acid supplementation and patient characteristics, 
etc. (Barden et al., 2016; Chiang and Serhan, 2017). Moreover, 
dietary supplementation in DHA (1.7g/j) and EPA (0.6g/j) for 6 
months increased the RvD1 released by blood mononuclear cells 
in Alzheimer’s disease patients as compared with controls (Wang 
et al., 2015). Results from intervention studies show that EPA 
and DHA dietary supplementation increases EPA- and DHA-
derived oxylipins although with high inter-individual variances 
(Ostermann et al., 2017).
In animals, a 3-week fish oil supplementation in arthritic mice 
increases synthesis of n-3 PUFA-derived SPMs associated with a 
diminished production of pro-inflammatory mediators (Norling 
et al., 2016). n-3 PUFA dietary supplementation (140 mg 
EPA+110 mg DHA/kg animal) in aged rats for 10 weeks enhances 
the production of lipid mediators derived from DHA and EPA 
in the cerebral cortex (Hashimoto et al., 2015). DHA and EPA 
supply also decreases the n-6 PUFA-derived metabolites (which 
are mainly pro-inflammatory) and increases the n-3 PUFA-
derived metabolites in the plasma and at the periphery both in 
mice (Balvers et al., 2012; Lazic et al., 2014) and rats (Hashimoto 
et al., 2015). A diet enriched with fish oil (containing 9% EPA + 
9% DHA) for 8 weeks in mice increases plasmatic RvD1 (Shevalye 
et al., 2015). In Fat-1 mice, brain EPA increase is accompanied 
by an increase in EPA-derived HEPEs (Siegert et al., 2017). 
Conversely, an n-6 PUFA dietary supply from weaning to 15 
weeks of age increases the n-6 PUFA metabolites and decreases 
the EPA-derived metabolites in the cortex and the plasma of 
rats (Taha et al., 2016). Recently, we showed that, in mice, n-3 
LC-PUFA supplementation from weaning for 2 months induces 
n-3 LC-PUFA enrichment in the hippocampus and subsequently 
an increase in n-3 PUFA-derived SPMs and a decrease in n-6 
FIGURE 4 | Regulation of n-3 long-chain PUFA-derived SPMs by PUFA 
consumption and inflammation. IL, interleukine; LPS, lipopolysaccharides; 
PUFA, polyunsaturated fatty acids; SPM, specialized pro-resolving mediators; 
TNF, tumor necrosis factor.
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PUFA-derived mediators (Rey et al., 2019). Moreover, in response 
to LPS, n-3 LC-PUFA-deficient mice present a pro-inflammatory 
lipid mediator profile whereas n-3 LC-PUFA-supplemented 
mice display an anti-inflammatory profile in the hippocampus 
(Rey et  al., 2019). Indeed, the consumption of n-3 LC-PUFAs 
increases the EPA and DHA derivatives. Hashimoto et al. found 
the same in the cortex of aged rats (Hashimoto et al., 2015). These 
results differ from those of Trépanier et al. who found that, in a 
model of Fat-1 mice, a greater increase in brain DHA induced by 
dietary supply has no effect on the resolution of inflammation 
after an icv LPS injection (Trépanier et al., 2018).
SPM production is also finely tuned by the regulation of 
the enzymes in their biosynthesis pathway. A 15-week n-3 
PUFA-deficient diet increases the COX-2 expression in the 
prefrontal cortex of rats, suggesting an increase in AA-derived 
pro-inflammatory mediator levels (Rao et al., 2007). Conversely, 
a 15-week n-6 PUFA-deficient diet decreases brain COX-2 
expression in rats (Kim et al., 2011). Interestingly, Taha et 
al. showed that rats fed on an n-6 PUFA-deficient diet for 
15 weeks are protected from an increase in COX-2 observed 
in LPS-treated n-3 PUFA-deficient animals (Taha et al., 
2017). However, we showed that 2 months’ n-3 LC-PUFA 
dietary supplementation was not sufficient to modulate 
COX-2 expression in the brain of mice (Rey et al., 2019). 
An n-3 LC-PUFA diet increases 15-LOX expression in the 
hippocampus without changes in the 5-LOX expression 
(Gabbs et al., 2015). The increase in 15-LOX in the brain has 
also been described following a 15-week n-6 PUFA-deficient 
diet in rats (Kim et al., 2011). 15-LOX is responsible for many 
n-6 and n-3 PUFA derivatives. Those synthesized from AA 
drastically decrease, and those produced from DHA increase, 
following a diet enriched in n-3 PUFAs in both mice and rats 
(Ostermann et al., 2017; Shalini et al., 2017; Rey et al., 2019).
Results on 15-LOX functions on inflammation regulation 
are conflicting. 15-LOX was initially described as deleterious in 
neurodegenerative pathologies because it increased the oxidative 
stress and neuronal degeneration (Pratico et al., 2004; Chinnici 
et al., 2007; Di Meco et al., 2014; Wang et al., 2015; Yigitkanli et 
al., 2017). It alters the mitochondrial function of neurons and then 
induces neuronal death (Pallast et al., 2009). However, recent studies 
demonstrate the protective role of 15-LOX, particularly in cognition. 
An increase in its expression is associated with a better working 
memory (Sun et al., 2015; Shalini et al., 2017). Moreover, an increase 
in 15-LOX expression during cerebral ischemia is essential for the 
recovery of neurological functions after the ischemic event (Wang 
et al., 2017). These results suggest that 15-LOX has a beneficial role 
in acute inflammation (ischemia, LPS) and is deleterious in chronic 
inflammation (neurodegenerative pathologies). SPM production is 
also partly regulated by the availability of free PUFAs that are their 
precursors. Indeed, PLA2 activity also depends on PUFA dietary 
supply. An n-6 PUFA-deficient diet increases the iPLA2 that is 
responsible for the release of DHA from the membranes and a 
decrease in calcium sensitive cytosolic PLA2 (cPLA2) associated 
with the hydrolysis of AA from the membranes (Kim et al., 2011).
Lipid nutrition, to which people are exposed throughout 
their lives, seems to play a major role in the synthesis of 
bioactive SPMs.
Regulation of the n-3 PUFA-Derived SPMs 
by Inflammation
Numerous studies have highlighted that inflammation 
modulates lipid mediator synthesis at the periphery and in the 
brain (Figure 4).
In humans, Wang et al. showed that the RvD1 level in the 
cerebrospinal fluid (CSF) of Alzheimer’s disease patients is 
positively correlated with cognitive function (Wang et al., 2015). 
Moreover, 15-LOX was decreased in the CSF suggesting an 
alteration of the resolution of inflammation in Alzheimer’s patients.
In rats, brain ischemia increases the production of 5 of 
mono-, di- and tri-hydroxy-DHA derivatives (Farias et al., 
2008; Hennebelle et al., 2017). However, LPS icv injection does 
not impact the RvD1 level (Rosenberger et al., 2004; Taha et al., 
2017). We have recently shown that, in mice, ip LPS injection 
modifies the n-6 PUFA derivative profile but not n-3 LC-PUFA 
derivatives (Rey et al., 2019).
In vitro, most studies have been performed on peripheral 
immune cells. The lipid mediator profile in rodent neutrophils 
and macrophages changes with macrophage phenotype M1 or 
M2, or with the inflammatory stimulus in neutrophils (Dieter 
et al., 2002). Indeed, M2 macrophages produce more D resolvins, 
protectins and maresins and less AA-derived pro-inflammatory 
mediators than M1 macrophages (Dalli and Serhan, 2012).
Inflammation more drastically alters the expression of 
biosynthetic enzymes than an n-3 LC-PUFA dietary supply. 
In rats, traumatic brain injury increases the COX-2, 5-LOX, 
15-LOX and CYP450 expression in the hippocampus and 
cortex, suggesting an alteration of all lipid mediator biosynthesis 
pathways (Birnie et al., 2013). LPS also regulates the expression of 
these enzymes. An icv LPS injection increases COX-2 expression 
and activity in the brain in mice (Rey et al., 2019) and rats. 
Moreover, in in vitro human monocytes and dendritic cells, anti-
inflammatory cytokines IL-4 or IL-13 increase the production 
of 15-LOX and decrease the production of 5-LOX (Nassar et al., 
1994; Spanbroek et al., 2001).
Neuroinflammation also modifies SPM receptor expression. 
Indeed, we show that LPS increases significantly the expression 
of RvD1 and RvE1 receptors (ALX/Fpr2 and ChemR23, 
respectively) in BV-2 microglial cells (Rey et al., 2016). The 
increase in ALX/Fpr2 expression was also detected in monocytes, 
in the hippocampus and in the cortex and in microglial cells in 
response to an inflammatory stimulus (Krishnamoorthy et al., 
2010; Wang et al., 2011; Wang et al., 2015; Guo et al., 2016). Then, 
inflammation activates the SPM signaling pathway in the brain to 
regulate the inflammatory response.
HUMAN TRANSLATION
Several possibilities can be considered to translate the findings 
described above and then attenuate the inflammatory tone, 
amplitude and duration of inflammation. The first one is to 
increase the local production of n-3 LC-PUFA-derived SPMs. 
We see that dietary means is a good way to modulate the level 
of the fatty acids from which they are synthesized and then 
to modify their synthesis. The SPM profile synthesized by 
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each individual could be responsible for the differences in the 
effects of n-3 PUFA obtained in humans. SPM profiles should 
be established in patients with different acute and chronic 
inflammatory pathologies, and in mice under the same 
conditions to find markers of neuroinflammation in the plasma 
that can be transposed to humans. Thanks to new technologies 
in liquid chromatography mass spectrometry (LC-MS/
MS), specific mediators produced during physiological and 
non-physiological conditions should be identified, allowing 
patient stratification according to disease severity. It could be 
interesting to determine an individual metabolomic profile to 
define personalized nutrition (n-3 PUFAs and doses) allowing 
an increase of n-3 PUFA-derived SPMs in the target tissue. 
Indeed, there are individual differences in diets and in n-3 
PUFA supplementation and also in nutrient metabolism 
and biological responses to food/nutrients. The aim of 
personalized nutrition is to increase health using nutrition by 
delivering specific personalized intervention suited to each 
individual based on the individual’s nutritional phenotype, 
metabolic profile, and environmental factors in order to 
prevent and treat chronic disease. Personalized nutrition can 
also be applied to healthy people. It is nowadays accessible 
because of a better understanding of the mechanisms of the 
effect of nutrition on health and also because of the progress 
in technologies enabling the identification of specific 
markers. Personalized nutrition has already shown its efficacy, 
especially in the Food4Me study involving >1600 participants 
from 7 European countries and in a systematic review and 
meta-analysis showing a greater efficacy of personalized 
nutrition in changing diet than a conventional approach 
(Celis-Morales et al., 2018).
The second possibility for taking advantage of research on 
the resolution of inflammation is to administer exogenous 
SPMs. Serhan defines a new concept of resolutive pharmacology 
targeting the development of SPM analogs, resistant to local 
inactivation, to stimulate natural circuits of resolution (Chiang 
and Serhan, 2017). The objective of this new therapeutic pathway 
is to administer these analogs in association with classical therapy 
in order to decrease the doses, thus limiting the secondary 
effects. A clinical trial has reported for the first time the efficacy 
of an RvE1 analog in patients with dry eye symptoms (Resolvyx 
Pharmaceuticals). These encouraging results should be extended 
to the use of such molecules to treat other inflammatory diseases.
CONCLUSION
In the investigation of new anti-inflammatory treatments 
without the secondary effects of traditional therapy, SPMs are 
promising therapeutic compounds: they are of natural origin 
and are active at low concentrations (nM) as compared with 
their precursor (µM) (Ariel and Serhan, 2007; Bannenberg 
and Serhan, 2010). SPMs are detectable in the brain and their 
level can be modulated by dietary supplementation. They have 
potent anti-inflammatory and pro-resolutive properties and we 
confirm the main role of nutrition as an environmental factor 
that greatly influences the inflammatory response. It is important 
to determine if inflammatory pathologies are due to unresolved 
inflammation, attributed to a decrease in n-3 LC-PUFA dietary 
intake leading to a decrease in SPM levels, to an enzyme or 
receptor polymorphism, to a de-regulation of SPM receptors or 
to a decrease in their expression. We should also determine if 
these mechanisms could be restored by n-3 LC-PUFA or SPM 
analog administration.
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